Medpace Holdings, Inc. (NASDAQ:MEDP) Expected to Announce Quarterly Sales of $327.32 Million

Wall Street analysts predict that Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) will post $327.32 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Medpace’s earnings. The highest sales estimate is $327.90 million and the lowest is $326.50 million. Medpace posted sales of $259.97 million in the same quarter last year, which would indicate a positive year over year growth rate of 25.9%. The firm is scheduled to announce its next earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Medpace will report full year sales of $1.41 billion for the current year, with estimates ranging from $1.38 billion to $1.43 billion. For the next year, analysts forecast that the company will post sales of $1.63 billion, with estimates ranging from $1.52 billion to $1.75 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Medpace.

Medpace (NASDAQ:MEDPGet Rating) last released its quarterly earnings results on Sunday, February 13th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.07. The business had revenue of $308.55 million during the quarter, compared to the consensus estimate of $309.03 million. Medpace had a return on equity of 20.55% and a net margin of 15.92%. The company’s quarterly revenue was up 18.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.39 EPS.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, February 19th. Robert W. Baird boosted their target price on Medpace from $160.00 to $175.00 in a research note on Thursday, March 17th. Finally, assumed coverage on Medpace in a research note on Thursday, March 31st. They issued a “buy” rating on the stock.

Several large investors have recently bought and sold shares of MEDP. Wellington Management Group LLP raised its holdings in shares of Medpace by 602.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,143,453 shares of the company’s stock worth $216,433,000 after purchasing an additional 980,774 shares during the period. Norges Bank bought a new stake in Medpace during the 4th quarter valued at $57,343,000. Loomis Sayles & Co. L P raised its holdings in Medpace by 149.5% during the 4th quarter. Loomis Sayles & Co. L P now owns 233,242 shares of the company’s stock valued at $50,763,000 after acquiring an additional 139,767 shares during the period. Vulcan Value Partners LLC raised its holdings in Medpace by 37.0% during the 3rd quarter. Vulcan Value Partners LLC now owns 308,504 shares of the company’s stock valued at $58,394,000 after acquiring an additional 83,328 shares during the period. Finally, Stephens Investment Management Group LLC bought a new stake in Medpace during the 3rd quarter valued at $13,975,000. 96.88% of the stock is currently owned by institutional investors.

Shares of NASDAQ MEDP traded down $3.23 during midday trading on Friday, reaching $158.10. The company’s stock had a trading volume of 119,266 shares, compared to its average volume of 179,387. Medpace has a 12-month low of $136.80 and a 12-month high of $231.00. The firm has a 50 day moving average price of $156.99 and a 200-day moving average price of $185.66. The stock has a market capitalization of $5.32 billion, a P/E ratio of 32.87 and a beta of 1.48.

Medpace Company Profile (Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Stories

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with's FREE daily email newsletter.